Paragon Genomics, based in Hayward, Calif., develops targeted Next-Generation Sequencing (NGS) assays and technologies centered on its CleanPlex™ platform. CleanPlex has demonstrated advantages with low DNA input and degraded samples and has been adopted by more than 50 NGS labs globally. Notable adopters include groups at the University of California, USDA, CDC, Chinese Academy of Sciences and Annoroad Gene Technology. The company intends to use the Series A proceeds to develop additional NGS assay products, particularly in oncology and precision medicine. It also plans to expand its U.S. commercial team and grow its presence into Europe, Asia and South America via partnerships and distributorships. The $8M Series A provides capital to support these product and commercial expansion plans.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2017